



CrossMark  
click for updates

Cite this: RSC Adv., 2017, 7, 10816

Received 9th November 2016  
Accepted 4th February 2017

DOI: 10.1039/c6ra26543j  
[rsc.li/rsc-advances](http://rsc.li/rsc-advances)

## Cu(II)/DM-Segphos catalyzed asymmetric 1,3-dipolar cycloaddition of benzoisothiazole-2,2-dioxide-3-ylidene and azomethine ylides†

Feifei Li, Guorui Cao, Yanfeng Gao and Dawei Teng\*

Cu(OTf)<sub>2</sub>/DM-Segphos catalyzed asymmetric 1,3-dipolar cycloaddition between benzoisothiazole-2,2-dioxide-3-ylidene and azomethine ylides was studied. The spirocyclic products were obtained in high yields with up to >99 : 1 dr and 99% ee. The enantioselective cycloaddition could be explained by the coordination of the imino esters 2 and chiral ligand DM-Segphos to the metallic center. The *exo*-selective cycloaddition course was attributed to the steric repulsion between the dipolarophiles and the 3,5-dimethylphenylphosphine group of the ligand.

Benzosultams are an important privileged class of structures in drug discovery, and are attractive synthetic targets due to their biological activities and intermediates for constructing molecular complexity and diversity.<sup>1</sup> The catalytic asymmetric 1,3-dipolar cycloaddition reaction plays a crucial role in the enantioselective preparation of five-membered heterocycles.<sup>2</sup> More specifically, the asymmetric 1,3-dipolar cycloaddition of azomethine ylides with activated olefins has become one of the most powerful methods for the construction of chiral spirocyclic pyrrolidines containing spiro quaternary stereogenic centers,<sup>3</sup> which represent the key structural moiety widely present in a myriad of natural products and biologically active compounds.<sup>4</sup> Since the pioneering work of Gong<sup>5</sup> employing stoichiometric amounts of chiral organocatalyst, much attention has been paid to develop a catalytic asymmetric approach to synthesize spirocyclic pyrrolidines.<sup>6</sup> Although various methods are developed for this transformation, most dipolarophiles applied in these reactions are 2-oxoindolin-3-ylidene,<sup>6a–e</sup>  $\alpha$ -methylene- $\gamma$ -butyrolactone,<sup>6f,g</sup> ethyl cyclopropylidene acetate,<sup>6h</sup> 2-alkylidene-cycloketone,<sup>6i</sup> 5-alkylidene thia(oxa)zolidine-2,4-dione,<sup>6j</sup> and 3-alkylidene-4-chromanone.<sup>6k</sup>

In the past several years, our research has been focused on developing spiro benzoisothiazole dioxide derivatives, which have been known to exhibit a variety of biological activities.<sup>7,8</sup> To the best of our knowledge, there have no reports on catalytic asymmetric 1,3-dipolar cycloaddition of benzoisothiazole-2,2-dioxide-3-ylidene as the dipolarophile. Herein, we reported the first example of Cu(II)/DM-Segphos catalyzed asymmetric 1,3-

dipolar cycloaddition of benzoisothiazole-2,2-dioxide-3-ylidene derivatives with azomethine ylides to give spirocyclic products in high diastereoselectivity and enantioselectivity.


Our investigations began with a set of experiments directed at the identification of an optimal chiral Lewis acid system for the cycloaddition of benzoisothiazole-2,2-dioxide-3-ylidene **1a** with azomethine ylide precursor **2a** (Table 1). The initial reactions were performed with the combination of copper(II) trifluoromethanesulfonate and various chiral ligands as the chiral Lewis acid systems in dichloromethane at –15 °C. Under all reaction conditions, the *exo*-cycloadduct **3a** was obtained in excellent diastereoselectivities (>99 : 1). Reactions with PyBox ligand **L1**, **L2** led to the *exo*-cycloadduct **3a** in low yields with moderate enantioselectivities, while the use of bisoxazoline ligands **L3**, **L4** did not produce significant improvement (entry 1–4). Chiral ferrocene ligands **L5** and **L6** catalyzed the reaction efficiently to give *exo*-**3a** in good yields but also with moderate enantioselectivities (entry 5, 6). Chiral *P,P*-bidentate ligands **L7** and **L8** also could catalyze the reaction efficiently but with even lower enantioselectivities (entry 7, 8). Chiral *P,P*-axially ligands catalyzed the reaction efficiently with much better enantioselectivities (entry 9–12). Gratifyingly, we find that the bulky and electron-donating DM-Segphos ligand<sup>9</sup> **L11** catalyzed the reaction efficiently with excellent enantioselectivity. The spirocyclic product **3a** was obtained in 95% yield and 96% ee (entry 11). The other Cu(I/II) salts, such as Cu(CH<sub>3</sub>CN)<sub>4</sub>ClO<sub>4</sub> or Cu(CH<sub>3</sub>CN)<sub>4</sub>BF<sub>4</sub> and Cu(OAc)<sub>2</sub>, produced *exo*-**3a** in slightly lower yields and enantioselectivities in combination with ligand **L11** (entry 13–15).

Having identified a promising chiral Lewis acid system for the asymmetric 1,3-dipolar cycloaddition, we examined the effects of bases, solvents, and temperature on the reaction yield, diastereoselectivity, and enantioselectivity (Table 2). The

College of Chemical Engineering, Qingdao University of Science and Technology, Qingdao 266042, China


† Electronic supplementary information (ESI) available: Experimental procedures, full spectroscopic data for all new compounds, and crystal data for **3m** (CIF). CCDC 1515086. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c6ra26543j



**Table 1** The effects of ligands on the asymmetric 1,3-dipolar cycloaddition<sup>a</sup>

<sup>a</sup> Reaction condition: dipolarophile **1a** (0.1 mmol), imino ester **2a** (0.12 mmol), ligand (0.0077 mmol), Lewis acid (0.007 mmol), DBU (0.12 mmol), CH<sub>2</sub>Cl<sub>2</sub> (0.4 mL), -15 °C, 2 h. <sup>b</sup> Isolated yield. <sup>c</sup> Determined by HPLC analysis. <sup>d</sup> Determined by chiral HPLC analysis after purification.

reactions using triethylamine, DBU, DIPEA, and DABCO all afforded *exo*-**3a** with good diastereoselectivities and enantioselectivities (entry 1–4). High reaction yield was achieved when DBU was used, while the other bases gave low yields. Solvents have much effect on the reaction yields and enantioselectivities, but little on the diastereoselectivities. It was shown that dichloromethane is the best solvent of choice (entry 1 vs. 5–7). Investigation on the effect of temperature showed that the reaction yields could be slightly improved but the enantioselectivities were decreased when the reaction temperature was increased (entry 1, 8, 9). It was noted that higher enantiomeric excess (99% ee, entry 10 vs. 1) was achieved when the temperature was decreased from -15 °C to -25 °C. Even lower temperature caused adverse effect on both reactivity and enantioselectivity (entry 11). Optimization on the catalyst loading showed that both diastereoselectivity and enantioselectivity were reduced when lowering the catalytic loading from


**Table 2** The effects of reaction conditions on the asymmetric 1,3-dipolar cycloaddition<sup>a</sup>

<sup>a</sup> Reaction condition: dipolarophile **1a** (0.1 mmol), imino ester **2a** (0.12 mmol), DM-Segphos (0.0077 mmol), Cu(OTf)<sub>2</sub> (0.007 mmol), base (0.12 mmol), solvent (0.4 mL). <sup>b</sup> Isolated yield. <sup>c</sup> Determined by HPLC analysis. <sup>d</sup> Determined by chiral HPLC analysis after purification. <sup>e</sup> Reaction performed with a 5 mol% of catalyst.

7 mol% to 5 mol% (entry 12). Examination of different reaction times disclosed that 2 h was the best choice (entry 13, 14).

Under the optimized conditions, we next studied the Cu(II)/DM-Segphos catalyzed 1,3-dipolar cycloaddition of benzoisothiazole-2,2-dioxide-3-ylidene derivative **1a** with a variety of azemothione ylides. As summarized in Table 3, a wide array of imino esters **2a–l** derived from aromatic aldehyde reacted smoothly with **1a** affording the desired *exo*-adducts **3a–l** in good diastereoselectivities and enantioselectivities. The yields of the cycloadducts were sensitive to the position of the substituent on the phenyl group. Substrate with a *para*-substituent (4-Me) gave higher yield than that with a *meta*-substituent (3-Me) (**3b** vs. **3c**). It appeared that the electronic property of the benzene ring had very limited effect on the reaction yields and enantioselectivities. Both substrates with electron-donating substituents (Me, OMe) and those with electron-withdrawing ones (F, Cl, Br, CF<sub>3</sub>) gave the cycloadducts in high yields and enantioselectivities (**3b** and **3d** vs. **3e–h**). The imino ester **2i** derived from heteroaromatic aldehyde also gave **3i** in 87% yield and 94% ee. The imino ester **2j–l** with a much bulkier group ( $R^3 = t\text{Bu}$ ) led to *exo*-cycloadducts **3j–l** in good diastereoselectivity and enantioselectivity.



To further investigate the scope of the reaction, various benzoisothiazole-2,2-dioxide-3-ylidene derivatives **1b–i** were then examined under the optimal conditions. Regardless of the electronic properties, the electron-donating and electron-withdrawing substituents had no major effect on the reaction and led to *exo*-cycloadducts **3m–t** in moderate to good yields

**Table 3** Substrate scope of Cu(OTf)<sub>2</sub>/DM-Segphos catalyzed asymmetric 1,3-dipolar cycloaddition<sup>a</sup>

<sup>a</sup> General procedure: after a suspension of the DM-Segphos (0.0077 mmol) and Cu(OTf)<sub>2</sub> (0.007 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (0.2 mL) was stirred for 1 h at room temperature, a solution of the imino ester 2 (0.12 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (0.2 mL) was added. After being stirred at -25 °C for 10 min, DBU (0.12 mmol) and dipolarophile 1 (0.1 mmol) was added and the resulting solution was stirred at -25 °C for 2 h.

(65–95%), high diastereoselectivities (78 : 22 to >99 : 1 dr), and enantioselectivities (90% to 98% ee). The position of substituents on the benzyl ring had somewhat effect on the yields and enantiomeric excesses. Substrate with a *para*-substituent (4-Me, 95% yield, 98% ee) gave higher yield and enantioselectivity than that with an *ortho*- or *meta*-substituent (2-Me and 3-Me, 65–67% yield, 90–95% ee) (**3p** vs. **3n-o**). The substrates with alkyl and heteroaromatic substituents also gave the cycloadducts in good yields, high diastereoselectivities, and enantioselectivities (**3s** and **3t**). The absolute configuration of the product **3m** was determined by crystal structure analysis (Fig. 1). The absolute configurations of the other cycloadducts were determined by analogy.<sup>10</sup>

The stereochemical course of the reaction can be rationalized by means of the model proposed in Scheme 1.<sup>11</sup> Firstly, the complex **A** is generated by coordination of the imino esters **2** and the bidentate chiral ligand DM-Segphos to Cu(II) in a tetrahedral arrangement. After the abstraction of a proton by the

**Fig. 1** X-ray crystallography of compound **3m**.

amine base, the attack of benzoisothiazole-2,2-dioxide-3-ylidene **1** is favored to the *Si*-face avoiding the steric interaction with two 3,5-dimethylphenyl groups of the ligand. Finally, the steric repulsion between the sulfuryl group of dipolarophile and the substituent of the ligand inhibits the *endo*-orientation leading to high *exo*-selectivity for the Cu(II)/DM-Segphos catalyzed cycloaddition.

## Conclusions

In summary, we have developed a highly enantioselective Cu(II)/DM-Segphos catalytic system for the asymmetric 1,3-dipolar cycloaddition of azomethine ylides with benzoisothiazole-2,2-dioxide-3-ylidene. The corresponding spirocyclic adducts were afforded in good yields with high diastereo- and enantioselectivities under mild reaction conditions. Further investigations on the evaluation of alternative azomethine ylides that carry electron withdrawing groups other than esters, and the substituent tolerance of the benzoisothiazole-2,2-dioxide on the benzene ring are underway and will be reported in due course.

## Notes and references

- (a) K. C. Majumdar and S. Mondal, *Chem. Rev.*, 2011, **111**, 7749; (b) T. Mezei, N. Mesterházy, T. Bakó, M. Porcs-Makkay, G. Simig and B. Volk, *Org. Process Res. Dev.*, 2009,



- 13, 567; (c) L. N. Tumey, M. J. Robarge, E. Gleason, J. Song, S. M. Murphy, G. Ekema, C. Doucette, D. Hanniford, M. Palmer, G. Pawlowski, J. Danzig, M. Loftus, K. Hunady, B. Sherf, R. W. Mays, A. Stricker-Krongrad, K. R. Brunden, Y. L. Bennani and J. J. Harrington, *Bioorg. Med. Chem. Lett.*, 2010, **20**, 3287; (d) I. Fujita, T. Okumura, A. Sakakibara and Y. Kita, *J. Pharm. Pharmacol.*, 2012, **64**, 747; (e) S. H. Kim, R. Amu, S. W. Kwon, S.-H. Lee, C. H. Kim, S. K. Kang, S. D. Rhee, M. A. Bae, S. H. Ahn, D. C. Ha, H. G. Cheon, K. Y. Kim and J. H. Ahn, *Bioorg. Med. Chem. Lett.*, 2010, **20**, 1065; (f) M. Inagaki, T. Tsuri, H. Jyoyama, T. Ono, K. Yamada, M. Kobayashi, Y. Hori, A. Arimura, K. Yasui, K. Ohno, S. Kakudo, K. Koizumi, R. Suzuki, M. Kato, S. Kawai and S. Matsumoto, *J. Med. Chem.*, 2000, **43**, 2040; (g) Z. Brzozowski, F. Saczewiski and N. Neamati, *Bioorg. Med. Chem. Lett.*, 2006, **16**, 5298; (h) Y. Misu and H. Togo, *Org. Biomol. Chem.*, 2003, **1**, 1342; (i) G. J. Wells, M. Tao, K. A. Josef and R. Bihovski, *J. Med. Chem.*, 2001, **44**, 3488; (j) R. J. Cherney, R. Mo, D. T. Meyer, K. D. Hardman, R.-Q. Liu, M. B. Covington, M. Qian, Z. R. Wasserman, D. D. Christ, J. M. Trzasko, R. C. Newton and C. P. Decicco, *J. Med. Chem.*, 2004, **47**, 2981.
- 2 For reviews, see: (a) K. V. Gothelf, in *Cycloaddition Reactions in Organic Synthesis*, ed. S. Kobayashi and K. A. Jørgensen, Wiley-VCH, Weinheim, Germany, 2002, p. 211; (b) K. V. Gothelf and K. A. Jørgensen, in *Synthetic Applications of 1,3-Dipolar Cycloaddition Chemistry Toward Heterocycles and Natural Products*, ed. A. Padwa and W. Pearson, Wiley & Sons, New York, 2002, ch. 12, p. 817; (c) K. V. Gothelf and K. A. Jorgensen, *Chem. Rev.*, 1998, **98**, 863; (d) S. Kanemasa, *Synlett*, 2002, 1371; (e) H. Pellissier, *Tetrahedron*, 2007, **63**, 2887; (f) L. M. Stanley and M. P. Sibi, *Chem. Rev.*, 2008, **108**, 5366; (g) A. Bădoi, Y. Brinkmann, F. Viton and E. P. Kündig, *Pure Appl. Chem.*, 2008, **80**, 1013; (h) W. M. Golebiewski and M. Guema, *J. Heterocycl. Chem.*, 2008, **45**, 1687; (i) S. Kanemasa, *Heterocycles*, 2010, **82**, 87; (j) M. Kissane and A. R. Maguire, *Chem. Soc. Rev.*, 2010, **39**, 845; (k) C. Nájera, J. M. Sansano and M. Yus, *J. Braz. Chem. Soc.*, 2010, **21**, 377; (l) Y. Xing and N.-X. Wang, *Coord. Chem. Rev.*, 2012, **256**, 938; (m) T. Hashimoto and K. Maruoka, *Chem. Rev.*, 2015, **115**, 5366.
- 3 (a) P. R. Sebahar and R. M. Williams, *J. Am. Chem. Soc.*, 2000, **122**, 5666; (b) P. R. Sebahar, H. Osada, T. Usui and R. M. Williams, *Tetrahedron*, 2002, **58**, 6311; (c) K. Ding, Y. Lu, Z. Nikolovska-Coleska, S. Qiu, Y. Ding, W. Gao, J. Stuckey, K. Krajewski, P. P. Roller, Y. Tomita, D. A. Parrish, J. R. Deschamps and S. Wang, *J. Am. Chem. Soc.*, 2005, **127**, 10130; (d) K. Ding, Y. Lu, Z. Nikolovska-Coleska, G. Wang, S. Qiu, S. Shangary, W. Gao, D. Qin, J. Stuckey, K. Krajewski, P. P. Roller and S. Wang, *J. Med. Chem.*, 2006, **49**, 3432; (e) K. Ding, G. Wang, J. R. Deschamps, D. A. Parrish and S. Wang, *Tetrahedron Lett.*, 2005, **46**, 5949; (f) P. R. Sebahar and R. M. Williams, *Heterocycles*, 2002, **58**, 563.
- 4 For examples, (a) M. M. M. Santos, *Tetrahedron*, 2014, **70**, 9735; (b) Z. Zhang, X.-J. Chu, J.-J. Liu, Q. Ding, J. Zhang, D. Bartkovitz, N. Jiang, P. Karnachi, S.-S. So, C. Tovar, Z. M. Filipovic, B. Higgins, K. Glenn, K. Packman, L. Vassilev and B. Graves, *ACS Med. Chem. Lett.*, 2014, **5**, 124; (c) A. I. Almansour, R. S. Kumar, F. Beevi, A. N. Shirazi, H. Osman, R. Ismail, T. S. Choon, B. Sullivan, K. McCaffrey, A. Nahhas, K. Parang and M. A. Ali, *Molecules*, 2014, **19**, 10033; (d) S. Hati, S. Tripathy, P. K. Dutta, R. Agarwal, R. Srinivasan, A. Singh, S. Singh and S. Sen, *Sci. Rep.*, 2016, **6**, 32213; (e) A. P. Antonchick, C. Gerding-Reimers, M. Catarinella, M. Schürmann, H. Preut, S. Ziegler, D. Rauh and H. Waldmann, *Nat. Chem.*, 2010, **2**, 735; (f) S. M. Rajesh, S. Perumal, J. C. Menendez, P. Yogeeshwari and D. Sriram, *Med. Chem. Commun.*, 2011, **2**, 626; (g) S. Shangary, D. Qin, D. McEachern, M. Liu, R. S. Miller, S. Qiu, Z. Nikolovska-Coleska, K. Ding, G. Wang, J. Chen, D. Bernard, J. Zhang, Y. Lu, Q. Gu, R. B. Shah, K. J. Pienta, X. Ling, S. Kang, M. Guo, Y. Sun, D. Yang and S. Wang, *Proc. Natl. Acad. Sci. U. S. A.*, 2008, **105**, 3933; (h) R. S. Kumar, A. I. Almansour, N. Arumugam, A. Basiri, Y. Kia and R. R. Kumar, *Aust. J. Chem.*, 2014, **68**, 863.
- 5 X.-H. Chen, Q. Wei, S.-W. Luo, H. Xiao and L.-Z. Gong, *J. Am. Chem. Soc.*, 2009, **131**, 13819.
- 6 For catalytic asymmetric 1,3-dipolar cycloaddition of azomethine ylides, see: (a) A. P. Antonchick, C. Gerding-Reimers, M. Catarinella, M. Schürmann, H. Preut, S. Ziegler, D. Rauh and H. Waldmann, *Nat. Chem.*, 2010, **2**, 735; (b) T.-L. Liu, Z.-Y. Xue, H.-Y. Tao and C.-J. Wang, *Org. Biomol. Chem.*, 2011, **9**, 1980; (c) L. Wang, X.-M. Shi, W.-P. Dong, L.-P. Zhu and R. Wang, *Chem. Commun.*, 2013, **49**, 3458; (d) W. Dai, X.-L. Jiang, Q. Wu, F. Shi and S.-J. Tu, *J. Org. Chem.*, 2015, **80**, 5737; (e) J.-X. Zhang, H.-Y. Wang, Q.-W. Jin, C.-W. Zheng, G. Zhao and Y.-J. Shang, *Org. Lett.*, 2016, **18**, 4774; (f) Q.-H. Li, T.-L. Liu, L. Wei, X. Zhou, H.-Y. Tao and C.-J. Wang, *Chem. Commun.*, 2013, **49**, 9642; (g) J. Castulik, J. Marek and C. Mazal, *Tetrahedron*, 2001, **57**, 8339; (h) T.-L. Liu, Z.-L. He, H.-Y. Tao, Y.-P. Cai and C.-J. Wang, *Chem. Commun.*, 2011, **47**, 2616; (i) T.-L. Liu, Z.-L. He, Q.-H. Li, H.-Y. Tao and C.-J. Wang, *Adv. Synth. Catal.*, 2011, **353**, 1713; (j) W.-L. Yang, F.-F. Tang, F.-S. He, C.-Y. Li, X. Yu and W.-P. Deng, *Org. Lett.*, 2015, **17**, 4822; (k) T.-L. Liu, Z.-L. He and C.-J. Wang, *Chem. Commun.*, 2011, **47**, 9600; (l) T.-L. Liu, Z.-L. He, H.-Y. Tao and C.-J. Wang, *Chem.-Eur. J.*, 2012, **18**, 8042; (m) K. Liu, H.-L. Teng, L. Yao, H.-Y. Tao and C.-J. Wang, *Org. Lett.*, 2013, **15**, 2250; (n) F. Shi, Z.-L. Tao, S.-W. Luo, S.-J. Tu and L.-Z. Gong, *Chem.-Eur. J.*, 2012, **18**, 6885; (o) X. Ma, Y. Zhu, Q. Sun, X. Li, J. Su, L. Zhao, Y. Zhao, S. Qiu, W. Yan, K. Wang and R. Wang, *Chem. Commun.*, 2015, **51**, 8789; (p) G. Zhu, B. Wang, X. Bao, H. Zhang, Q. Wei and J. Qu, *Chem. Commun.*, 2015, **51**, 15510.
- 7 (a) G. Cao, F. Long, Y. Zhao, Y. Wang, L. Huang and D. Teng, *Tetrahedron*, 2014, **70**, 9359; (b) G. Cao, Y. Wang, T. Cui, L. Huang and D. Teng, *RSC Adv.*, 2016, **6**, 22519.
- 8 (a) S. Petry, K.-H. Baringhaus, N. Tennagels and G. Mueller, US 20,050,070,533 A1, 2005; (b) M. A. Collins, V. A. Mackner, J. E. Wrobel, J. P. Edwards, T. K. Jones, C. M. Tegley and L. Zhi, US 6,339,098, 2002; (c) H. Masako, M. Sachiko,



- N. Hiroshi, K. Hiroki and M. Yukari, WO 2,005,092,858 A2, 2005.
- 9 For the use of Segphos ligands in catalytic asymmetric 1,3-dipolar cycloadditions of azomethine ylides, see: (a) R. Joseph, C. Murray and P. Garner, *Org. Lett.*, 2014, **16**, 1550; (b) M. González-Esguevillas, J. Adrio and J. C. Carretero, *Chem. Commun.*, 2013, **49**, 4649; (c) E. E. Maroto, S. Filippone, A. Martín-Domenech, M. Suarez and N. Martín, *J. Am. Chem. Soc.*, 2012, **134**, 12936; (d) J. Hernández-Toribio, S. Padilla, J. Adrio and J. C. Carretero, *Angew. Chem., Int. Ed.*, 2012, **51**, 8854; (e) M. González-Esguevillas, J. Adrio and J. C. Carretero, *Chem. Commun.*, 2012, **48**, 2149; (f) Y. Yamashita, T. Imaizumi and S. Kobayashi, *Angew. Chem., Int. Ed.*, 2011, **50**, 4893; (g) A. López-Pérez, J. Adrio and J. C. Carretero, *Angew. Chem., Int. Ed.*, 2009, **48**, 340; (h) Y. Oderaotoshi, W. Cheng, S. Fujitomi, Y. Kasano, S. Minakata and M. Komatsu, *Org. Lett.*, 2003, **5**, 5043.
- 10 CCDC 1515086 (**3m**) contains the supplementary crystallographic data for this paper.<sup>†</sup>
- 11 M. Potowski, A. P. Antonchick and H. Waldmann, *Chem. Commun.*, 2013, **49**, 7800.

